| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | CSAID Binding protein 1, CSBP1, CSBP2, EXIP, MAP kinase MXI2, MAPkinase p38alpha, MAPK14, p38 ALPHA, p38 MAP kinase, p38 mitogen activated protein kinase, RK, SAPK 2A, Stress activated protein kinase 2A |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | A 20 residue synthetic peptide based on the human p38 with the cysteine residue added and coupled to KLH |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
p38 is a member of the mitogen-activated protein kinase (MAPK) family, specifically involved in cellular responses to stress and inflammation. In the nervous system, p38 plays a pivotal role in regulating apoptosis, neuroinflammation, and synaptic plasticity—processes that are frequently dysregulated in neurodegenerative diseases.
Upon activation by environmental and cellular stressors such as oxidative damage, cytokines, and UV radiation, p38 translocates to the nucleus where it modulates transcription factors and pro-apoptotic proteins. This leads to the release of cytochrome c, activation of caspase-3, and cleavage of PARP, promoting programmed cell death.
In Alzheimer’s, Parkinson’s, and ALS, aberrant p38 signaling contributes to neuronal loss, glial activation, and neurodegenerative phenotypes. As a result, p38 has emerged as a therapeutic target for modulating neuroinflammation and preventing neuronal degeneration.
A 1:1000 dilution of SPC-172 was sufficient for detection of p38 in 20 µg of HeLa cell lysate by ECL immunoblot analysis.
Cite this product varies by variant:
- SPC-172D — Size: 100 uL: p38 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172D, RRID: AB_1055444)
- SPC-172D-A390 — Size: 100 uL: p38 Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172D-A390, RRID: AB_2703821)
- SPC-172D-A488 — Size: 100 uL: p38 Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172D-A488, RRID: AB_2703822)
- SPC-172D-A594 — Size: 100 uL: p38 Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172D-A594, RRID: AB_2703824)
- SPC-172D-APC — Size: 100 uL: p38 Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172D-APC, RRID: AB_2703830)
- SPC-172D-BI — Size: 100 uL: p38 Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172D-BI, RRID: AB_2703831)
- SPC-172D-FITC — Size: 100 uL: p38 Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172D-FITC, RRID: AB_2703832)
- SPC-172D-HRP — Size: 100 uL: p38 Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172D-HRP, RRID: AB_2703833)
- SPC-172D-PCP — Size: 100 uL: p38 Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172D-PCP, RRID: AB_2703835)
- SPC-172D-RPE — Size: 100 uL: p38 Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172D-RPE, RRID: AB_2703836)
- SPC-172S — Size: 12 uL: p38 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-172S, RRID: AB_1055444)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Fan Y., et al (2007) Mol. Cells 23 (1): 30-38.
3. Han J., et al. (1994) Science 265: 808-811.
4. Van L. A., et al. (2004) Faseb J. 18: 1946−1948.
5. Deng et al. (2003) Cell 115: 61-70.
6. Salojin K.V., et al. (2006) J Immunol. 176 (3):1899-907.
7. Medicherla S., et al. (2006) J Pharmacol Exp Ther. 318(1): 99-107.
